A detailed history of Argyle Capital Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Argyle Capital Partners, LLC holds 9,474 shares of ABBV stock, worth $2.22 Million. This represents 1.57% of its overall portfolio holdings.

Number of Shares
9,474
Previous 9,540 0.69%
Holding current value
$2.22 Million
Previous $1.77 Billion 23.88%
% of portfolio
1.57%
Previous 1.46%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$184.85 - $231.54 $12,200 - $15,281
-66 Reduced 0.69%
9,474 $2.19 Billion
Q2 2025

Aug 13, 2025

SELL
$170.16 - $206.27 $19,398 - $23,514
-114 Reduced 1.18%
9,540 $1.77 Billion
Q1 2025

Aug 13, 2025

SELL
$169.2 - $216.66 $104,904 - $134,329
-620 Reduced 6.03%
9,654 $2.02 Billion
Q4 2024

Aug 13, 2025

BUY
$164.99 - $203.87 $1.7 Million - $2.09 Million
10,274 New
10,274 $1.83 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Argyle Capital Partners, LLC Portfolio

Follow Argyle Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Argyle Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Argyle Capital Partners, LLC with notifications on news.